兽医传染病治疗市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

兽医传染病治疗市场按产品类型(抗生素、抗病毒药物、抗真菌药物、杀阿米巴药等)、动物类型和地理区域细分

市场快照

CAGR
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 5.8 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

微生物是无处不在的微小生物,例如细菌和病毒。数千种微生物中很少有侵入、繁殖并在动物和人类中引起疾病​​。大多数微生物生活在皮肤、口腔、上呼吸道和肠道上,不会引起任何有害疾病,但有些微生物生活在宠物体内或身上,或侵入并引起疾病,这取决于微生物的性质和状态。宠物的自然防御。 

据世界小动物兽医协会 (WSAVA) 估计,60% 至 80% 的新发疾病是人畜共患病,这表明兽医在传染病的识别、预防和控制中的重要性。例如,裂谷热是非洲和中东的一种地方性人畜共患病,每年给生产者造成 4.27 亿美元的损失。由于人口规模的增加,传染病流行率的增加以及对奶制品、肉类和家禽产品的需求增加是兽医传染病治疗市场的关键驱动因素。

报告范围

根据报告的范围,兽医传染病是可以从一种动物传播到另一种动物或人类的疾病。尽管数量巨大,但数十万种微生物中相对较少的微生物入侵、繁殖并导致动物和人类疾病。

By Product Type
Antibiotics
Antiviral
Antifungal
Amebicides
Others
By Animal Type
Dogs and Cats
Horses
Swine
Poultry
Other Animals
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

主要市场趋势

抗生素板块有望在兽用传染病治疗市场占据主要市场份额

抗生素药物通常用于兽医治疗由细菌和其他微生物引起的传染病。不同类别的抗生素可用于治疗动物的传染病,包括青霉素类、头孢菌素类、头霉素类、氨基糖苷类等。人畜共患病是由在动物和人类之间传播的感染、生物和寄生虫引起的传染病。根据美国疾病预防控制中心的数据,2017年,人畜共患病导致食源性疾病24484人、住院5677人、死亡122人。

因此,由于人畜共患疾病数量的增加,以及宠物拥有量的增加和兽医疗法研究与开发 (R&D) 活动的增加,预计将推动市场增长。

Pet Ownership.png

北美预计将在市场上占有重要份额,预计在预测期内也将如此

由于兽医传染病的流行率上升,该地区的伴侣动物保健支出增加,北美预计将在全球兽医传染病治疗市场占据主要市场份额。根据美国心丝虫协会的数据,2013 年至 2016 年间,在美国及其领土上,每个诊所被诊断出患有心丝虫的狗的数量增加了 21%。此外,增加对兽药产品的采用和兽医传染病治疗技术的进步是在很大程度上推动了整个区域市场的增长。

 Veterinary Infectious Disease Therapeutics Market 2

竞争格局

兽医传染病治疗市场竞争适度,由几个主要参与者组成。就市场份额而言,目前很少有主要参与者占据市场主导地位。一些主要的市场参与者包括 Elanco、默克公司、勃林格殷格翰 Vetmedica、Zoetis、Dechra Pharmaceuticals PLC、Ceva Sante、Virbac SA、Bayer AG、Vetoquinol SA、IDEXX Laboratories, Inc。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Infectious Diseases in Animals

      2. 4.2.2 Technological Advancements in Development of New Drugs

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Government Regulations

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product Type

      1. 5.1.1 Antibiotics

      2. 5.1.2 Antiviral

      3. 5.1.3 Antifungal

      4. 5.1.4 Amebicides

      5. 5.1.5 Others

    2. 5.2 By Animal Type

      1. 5.2.1 Dogs and Cats

      2. 5.2.2 Horses

      3. 5.2.3 Swine

      4. 5.2.4 Poultry

      5. 5.2.5 Other Animals

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Elanco

      2. 6.1.2 Merck & Co. Inc

      3. 6.1.3 Boehringer Ingelheim Vetmedica, Inc.

      4. 6.1.4 Zoetis Inc.

      5. 6.1.5 Dechra Pharmaceuticals PLC

      6. 6.1.6 Ceva Santé Animale

      7. 6.1.7 Virbac S.A

      8. 6.1.8 Bayer AG

      9. 6.1.9 Vetoquinol S.A

      10. 6.1.10 IDEXX Laboratories, Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Veterinary Infectious Disease Therapeutics Market market is studied from 2018 - 2026.

The Veterinary Infectious Disease Therapeutics Market is growing at a CAGR of 5.8% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Elanco, Merck & Co. Inc, Boehringer Ingelheim Vetmedica, Zoetis, Dechra Pharmaceuticals PLC are the major companies operating in Veterinary Infectious Disease Therapeutics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!